Aadi Bioscience (AADI) has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates, or ADCs, in collaboration with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, and Hangzhou DAC. Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging Hangzhou DAC’s CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 or PTK7, Mucin-16 or MUC16 and Seizure Related 6 Homolog or SEZ6. Aadi will pay aggregate upfront payments of $44M for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265M, cumulative commercial milestone payments of up to $540M and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity, or PIPE, financing that is expected to result in gross proceeds of approximately $100M, before deducting placement agent fees and other offering expenses. The syndicate was led by Ally Bridge Group. The PIPE financing is expected to close in 1H25, subject to stockholder vote and satisfaction of customary closing conditions.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AADI:
- Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks
- Aadi Bioscience Reports Q3 2024 Earnings and Growth
- Aadi Bioscience reports Q3 EPS (46c), consensus (46c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
